Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation.

Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takana T, Holtzman DM, Nedergaard M, Deane R.

Mol Neurodegener. 2016 Dec 8;11(1):74. Erratum in: Mol Neurodegener. 2017 Jan 12;12 (1):3.

2.

Mechanisms of Aβ Clearance and Degradation by Glial Cells.

Ries M, Sastre M.

Front Aging Neurosci. 2016 Jul 5;8:160. doi: 10.3389/fnagi.2016.00160. eCollection 2016. Review.

3.

Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism.

Mahley RW.

Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1305-15. doi: 10.1161/ATVBAHA.116.307023. Epub 2016 May 12. Review.

4.

ApoE4 upregulates the activity of mitochondria-associated ER membranes.

Tambini MD, Pera M, Kanter E, Yang H, Guardia-Laguarta C, Holtzman D, Sulzer D, Area-Gomez E, Schon EA.

EMBO Rep. 2016 Jan;17(1):27-36. doi: 10.15252/embr.201540614. Epub 2015 Nov 12.

5.

The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease.

Inekci D, Jonesco DS, Kennard S, Karsdal MA, Henriksen K.

Front Neurol. 2015 May 11;6:90. doi: 10.3389/fneur.2015.00090. eCollection 2015. Review.

6.

Role of the APOE ε2/ε3/ε4 polymorphism in the development of primary open-angle glaucoma: evidence from a comprehensive meta-analysis.

Song Q, Chen P, Liu Q.

PLoS One. 2013 Nov 27;8(11):e82347. doi: 10.1371/journal.pone.0082347. eCollection 2013.

7.

Apolipoprotein E as a β-amyloid-independent factor in Alzheimer's disease.

Wolf AB, Valla J, Bu G, Kim J, LaDu MJ, Reiman EM, Caselli RJ.

Alzheimers Res Ther. 2013 Sep 3;5(5):38. doi: 10.1186/alzrt204. eCollection 2013. Review.

8.

Sporadic Alzheimer's disease begins as episodes of brain ischemia and ischemically dysregulated Alzheimer's disease genes.

Pluta R, Jabłoński M, Ułamek-Kozioł M, Kocki J, Brzozowska J, Januszewski S, Furmaga-Jabłońska W, Bogucka-Kocka A, Maciejewski R, Czuczwar SJ.

Mol Neurobiol. 2013 Dec;48(3):500-15. doi: 10.1007/s12035-013-8439-1. Epub 2013 Mar 22. Review.

9.

The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-β peptide in the brain.

Carlo AS, Gustafsen C, Mastrobuoni G, Nielsen MS, Burgert T, Hartl D, Rohe M, Nykjaer A, Herz J, Heeren J, Kempa S, Petersen CM, Willnow TE.

J Neurosci. 2013 Jan 2;33(1):358-70. doi: 10.1523/JNEUROSCI.2425-12.2013.

10.

Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Mahley RW, Huang Y.

Neuron. 2012 Dec 6;76(5):871-85. doi: 10.1016/j.neuron.2012.11.020. Review.

11.

APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease.

Wolf AB, Caselli RJ, Reiman EM, Valla J.

Neurobiol Aging. 2013 Apr;34(4):1007-17. doi: 10.1016/j.neurobiolaging.2012.10.011. Epub 2012 Nov 16. Review.

12.

Cholesterol: its regulation and role in central nervous system disorders.

Orth M, Bellosta S.

Cholesterol. 2012;2012:292598. doi: 10.1155/2012/292598. Epub 2012 Oct 17.

13.

Alzheimer mechanisms and therapeutic strategies.

Huang Y, Mucke L.

Cell. 2012 Mar 16;148(6):1204-22. doi: 10.1016/j.cell.2012.02.040. Review.

14.

Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons.

Chen HK, Liu Z, Meyer-Franke A, Brodbeck J, Miranda RD, McGuire JG, Pleiss MA, Ji ZS, Balestra ME, Walker DW, Xu Q, Jeong DE, Budamagunta MS, Voss JC, Freedman SB, Weisgraber KH, Huang Y, Mahley RW.

J Biol Chem. 2012 Feb 17;287(8):5253-66. doi: 10.1074/jbc.M111.276162. Epub 2011 Dec 12.

15.

Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors.

Brodbeck J, McGuire J, Liu Z, Meyer-Franke A, Balestra ME, Jeong DE, Pleiss M, McComas C, Hess F, Witter D, Peterson S, Childers M, Goulet M, Liverton N, Hargreaves R, Freedman S, Weisgraber KH, Mahley RW, Huang Y.

J Biol Chem. 2011 May 13;286(19):17217-26. doi: 10.1074/jbc.M110.217380. Epub 2011 Mar 18.

16.

Neighborhood psychosocial environment, apolipoprotein E genotype, and cognitive function in older adults.

Lee BK, Glass TA, James BD, Bandeen-Roche K, Schwartz BS.

Arch Gen Psychiatry. 2011 Mar;68(3):314-21. doi: 10.1001/archgenpsychiatry.2011.6.

17.

Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

Srinivasan V, Kaur C, Pandi-Perumal S, Brown GM, Cardinali DP.

Int J Alzheimers Dis. 2010 Dec 8;2011:741974. doi: 10.4061/2011/741974.

18.

Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease.

Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, Freedman SB, Weisgraber KH, Huang Y, Mahley RW.

J Biol Chem. 2011 Feb 18;286(7):5215-21. doi: 10.1074/jbc.M110.151084. Epub 2010 Nov 30.

19.

Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice.

Andrews-Zwilling Y, Bien-Ly N, Xu Q, Li G, Bernardo A, Yoon SY, Zwilling D, Yan TX, Chen L, Huang Y.

J Neurosci. 2010 Oct 13;30(41):13707-17. doi: 10.1523/JNEUROSCI.4040-10.2010.

20.

Apolipoprotein E: from lipid transport to neurobiology.

Hauser PS, Narayanaswami V, Ryan RO.

Prog Lipid Res. 2011 Jan;50(1):62-74. doi: 10.1016/j.plipres.2010.09.001. Epub 2010 Sep 18. Review.

Supplemental Content

Support Center